Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19965342 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL29039394 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL7993095 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL6159240 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL16551786 | 1.00 | HSD17B10 (0.43) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL7978668 | 0.96 | EPHX1 (0.40) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL7978671 | 0.96 | EPHX1 (0.40) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL6158638 | 0.96 | EPHX1 (0.40) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL5744460 | 0.86 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 | |
| SCHEMBL5744462 | 0.86 | HSD17B10 (0.48) | HSD17B10SMN1; SMN2NPC1ALDH1A1UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12134609-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-11-05 | — | — | US | disclosed |
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2024-03-21 | — | — | US | disclosed |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2024-01-16 | — | — | US | disclosed |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | IMMUNESENSOR THERAPEUTICS, INC. (US) | 2023-03-16 | — | — | US | disclosed |
| WO-2018049271-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | FLX BIO, INC. (US) | 2018-03-15 | — | — | WO | disclosed |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | RAPT THERAPEUTICS, INC. | 2018-03-15 | — | — | US | disclosed |
| WO-2015028409-A1 | 6,7-DIHYDRO-5H-BENZO[7]ANNULENE DERIVATIVES, METHOD FOR THE PREPARATION THEREOF, PHARMACEUTICAL PREPARATIONS COMPRISING THEM, AND THE USE THEREOF FOR PRODUCING MEDICAMENTS | BAYER PHARMA AKTIENGESELLSCHAFT (DE) | 2015-03-05 | — | — | WO | disclosed |
| US-6228872-B1 | PEPTIDE-PROLYL ISOMERASE AND ROTAMASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2001-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240092760-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | HSD17B10 2690/4885SMN1; SMN2 2633/4885NPC1 667/4885 |
| US-11873291-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HSD17B10 2690/4885SMN1; SMN2 2633/4885NPC1 667/4885 |
| US-12134609-B2 | Quinoline cGAS antagonist compounds | CGAS, GLS2, GLS | HSD17B10 2690/4885SMN1; SMN2 2633/4885NPC1 667/4885 |
| US-20180072743-A1 | CHEMOKINE RECEPTOR MODULATORS AND USES THEREOF | ACKR3, CCR5, CXCR3 | HSD17B10 2376/4885SMN1; SMN2 4865/4885NPC1 1465/4885 |
| US-20230081291-A1 | QUINOLINE cGAS ANTAGONIST COMPOUNDS | CGAS, GLS2, GLS | HSD17B10 2690/4885SMN1; SMN2 2633/4885NPC1 667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.